LWAY

Lifeway is a genuinely good small-cap business hiding inside a rich stock. Revenue has compounded from $119M (FY2021) to $212M (FY2025) — roughly 15% a year — and FY2025 was the best year of the run: sales +13.7%, gross profit +19.8% (margin expanding to 27.4%), operating income +16.7%, and net income +53.6% to $13.9M for a 16.1% ROE. The balance sheet is pristine: liabilities/equity of just 0.23x, $85.8M of equity, $88.7M retained earnings, and negligible long-term debt. This is exactly the 'consistent, profitable growth' the fundamentals lens rewards, and it's why this is not a sell.

What stops it being a buy is the price and the cash statement. At $30.94 the stock trades at 34.8x FY diluted EPS of $0.89 — a full multiple for a dairy company with a 6.5% net margin, where one soft year (as in FY2022's $924K net income) would make that P/E look ugly. Net income has been lumpy ($3.31M → $924K → $11.4M → $9.03M → $13.9M), so the trailing 48% EPS jump is partly a rebound, not a durable run-rate to extrapolate. More importantly, capex exploded +308.6% to $27.4M against $10.9M of operating cash flow (itself down 15.5%), so free cash flow was deeply negative and cash fell 66.7% to just $5.57M. That capacity build can drive the next growth leg — but until it converts to sales and FCF, the market is paying 34.8x for a story, not proven output.